Circulating endothelial progenitor cells (cEPCs) play an important role in cancer development. Previous studies showed that serum carcinoembryonic antigen (CEA) levels and the number of circulating endothelial progenitor cells (cEPCs) in the peripheral blood are both involved in tumor neoangiogenesis, and can be used for monitoring tumor progression, recurrence, metastasis, and therapeutic responses. However, the clinical relevance of these biomarkers remains unknown. In this study, 40 colorectal cancer (CRC) patients and 17 healthy volunteers were recruited and the amount of cEPCs in the peripheral blood was measured by flow cytometry. The serum CEA level was determined by CEA-RIACT assay. Results showed that cEPC level positively correlated with the stage of the disease, but not with the age and gender of the patients. Moreover, patients with higher serum CEA levels had higher cEPC levels. These results provide clinical evidence for a correlation between two commonly used biomarkers. Further understanding the role of serum CEA in cEPC-mediated tumor vascularization may improve clinical CRC diagnosis and provide useful insights into the design of therapeutic interventions that target tumor vasculature.
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cause of cancer-related deaths worldwide [1] . Anatomically, CRC develops in the lining of the colon or rectum, and its prognosis can be improved by early detection and surgical removal [2] . Therefore, identification of clinical biomarkers that can detect CRC at an early stage and during the course of the disease with proper sensitivity and specificity is of paramount importance for the treatment of this deadly disease [3] . A large number of researches have focused on identifying molecular markers based on DNA, RNA, or proteins to develop novel biomarkers in blood and stool for the detection of CRC. Moreover, recent integrated molecular analyses of human CRCs have revealed new biomarkers, including RAS, BRAF mutations, microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) status, which have broadened our understanding of CRC pathogenesis. Additionally, some of these biomarkers have been translated to patient care [4, 5] .
Among the commonly used clinical biomarkers, the carcinoembryonic antigen (CEA) [6, 7] , a cell surface adhesion molecule of the immunoglobulin superfamily that was found to play a role in tumor cell survival, apoptosis, and metastasis [8] [9] [10] [11] , is in routine clinical use to monitor pre-operative disease progression as well as tumor recurrence and metastasis [12] . Recently, a link between serum CEA and endothelial cell (EC) activation during tumor neoangiogenesis was established [13] . It was also found that soluble CEA released by tumor cells promotes pro-angiogenic endothelial behaviors through activation of integrin signaling, resulting in enhanced tumor vascularization in CRCs with higher serum levels of soluble CEA, conferring upon this molecule a functional role in tumor angiogenesis [8] .
One of the hallmarks of cancer is tumor neoangiogenesis, which ensures tumor growth and metastasis. Traditionally, it is believed that tumors acquire vasculature only through angiogenesis, in which new blood vessels form from pre-existing ones. Once thought to occur only during embryonic development, vasculogenesis is now believed to play an important role in the formation of tumor vasculature [14] . This process involves activation and recruitment of bone marrow-derived endothelial progenitor cells (EPCs) to the tumor mass where they either differentiate into mature ECs or promote new blood vessel formation by secreting pro-angiogenic factors in a paracrine manner [14] [15] [16] [17] . Classically, EPCs are characterized by the expressions of surface markers CD34, CD133, and vascular endothelial growth factor receptor-2 (VEGFR-2, or CD309) [15] , and can give rise to circulating EPCs (cEPCs) that are involved in postnatal vasculogenesis, including wound healing, tissue repair, and pathological conditions such as tumor vascularization [18] . The findings that EPCs are involved in tumor neovascularization, and that the number of cEPCs in the peripheral blood is increased in many types of cancers, including CRC, make them potential markers for monitoring tumor progression and therapeutic responses [18] [19] [20] [21] [22] [23] [24] [25] [26] .
In this study, we analyzed the serum level of the protein biomarker CEA and the cEPC level in peripheral blood samples of CRC patients. We further correlated these markers with other clinical pathologic characteristcs such as age, gender, and tumor stage of the patients. Our results have clinical implications for the treatment of CRC.
Materials and Methods

Patients
A total of 40 CRC patients (27 males and 13 females with a median age of 56 years, ranging from 24-77 years) were diagnosed and recruited at Union Hospital in Wuhan, China. Patients with cardiovascular diseases, severe hypertension, diabetes, inflammatory diseases, severe acute ischemia or a recent history (within 3 months) of taking drugs for mobilizing hemopoiesis were excluded. Informed consent was obtained from each patient and the study was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Permit Number: S073).
Antibodies and reagents
The FITC-conjugated anti-CD34, PE-conjugated anti-CD133, and APC-conjugated anti-CD309 were obtained from Miltenyi Biotec (San Diego, USA). Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Hypaque density gradient centrifugation (TBD Science, Beijing, China) according to the manufacturer's instructions. FITC-, PE-and APC-conjugated isotype immunoglobulin G (IgG) were obtained from BD Biosciences (San Jose, USA). Bovine serum albumin (BSA) and NaN 3 were obtained from Biossci Company (Shanghai, China).
CEA detection assay
To measure the CEA level, peripheral blood samples were obtained from CRC patients preoperatively. The concentration of CEA was measured using the CEA-RIACT assay kit according to the manufacturer's instructions (CIS Bio International, Gif-sur-Yvette, France). Briefly, plasma samples were collected into tubes pre-coated with monoclonal antibodies against human CEA, followed by incubation with 125 I-labeled anti-CEA antibody. After extensive wash, radioactivity was measured with a gamma radiation counter GC-1200 (Zhongjia Photoelectric Instrument Company, Hefei, China). Detection levels of soluble CEA in serum for this kit are 1-200 ng/ml.
PBMC isolation and cEPC detection
In order to isolate cEPC, 3 ml of peripheral blood was collected from each CRC patient. The PBMCs were then isolated using a Ficoll-Paque density gradient centrifugation method according to the manufacturer's instructions (GE Healthcare, Chicago, USA). Briefly, diluted whole blood was layered on top of a gradient of Ficoll reagent in a conical tube, followed by centrifugation for 30 min at room temperature. The top plasma layer was then discarded, and the interface cell layer between plasma and Ficoll that contained the PBMCs was collected. PBMCs were then harvested and washed twice with phosphate buffered saline (PBS) containing 1% BSA. Cells were then incubated with the indicated antibodies for 30 min at 4°C in the dark. After incubation, cells were washed twice with PBS containing 1% NaN 3 and analyzed within 2 h with a flow cytometer (LSR II; Becton Dickinson, Franklin Lakes, USA).
Statistical analysis
Statistical analyses were performed using Prism 6.0 software (GraphPad Software Inc., San Diego, USA). All data are presented as the mean ± SD. Comparisons between two different groups were performed using Student's t-test. P values less than 0.05 were considered statistically significant.
Results
Association of CEA level with clinicopathologic features in CRC patients
In this study, 40 CRC patients were recruited with a median age of 56 years. Two patients (5%) were younger than 40 years, 19 (47.5%) were 40-59 years, and 18 (45%) were older than 60 years ( Table 1) . Among them, 27 were male and 13 were female. We determined the stage of the tumor for each CRC patient using the TNM tumor staging system [27] : 13 (32.5%) of the CRC patients had TNM Stage II tumors at the time of diagnosis, 20 (50%) had Stage III, and 7 (17.5%) had Stage IV tumors ( Table 1) . To measure serum CEA levels, peripheral blood samples were obtained from CRC patients preoperatively. Under normal physiologic conditions, less than 5 ng/ml of soluble CEA should be detected in serum, whereas serum CEA levels of more than 5 ng/ml should be considered pathological [12] . Using these criteria, 23 CRC patients had a high serum CEA level, while 17 had a physiological or normal level of CEA ( Table 1) . Among the available clinicopathologic features of the CRC patients, the stage of the tumor showed the strongest correlation with the level of serum CEA. Four out of 13 (30.8%) patients with TNM Stage II tumors had a high CEA level (≥5 ng/ml), with a median of 3.1 ng/ml (mean = 6.09 ng/ml); 6 out of 20 (30%) TNM III patients had high CEA with a median of 4.2 ng/ml (mean = 6.17 ng/ml). On the other hand, all seven TNM IV (100%) patients had high CEA level with a median of 51.2 ng/ml (mean = 45.77 ng/ml), which is significantly higher than those for TNM II and III patients ( Table 1 and Fig. 1A) . No association was found between CEA level and age or gender of the patients (Fig. 1B) . Taken together, these results showed that the serum CEA level of CRC patients was associated with the stage of the tumors, but not with gender or age of the patients. These results strengthened the evidence for the notion that CEA level can be used as a biomarker for CRC tumor progression.
Increased number of cEPCs in the peripheral blood of CRC patients
In order to analyze the cEPC levels in CRC patients and compare them with those of healthy individuals, we collected peripheral blood from 40 CRC patients and 17 healthy donors with age ranging from 20 to 56 years, and isolated PBMCs as described above. Flow cytometric analysis was then performed on these PBMCs using antibodies against CD34, CD133, and CD309 cell surface markers. As shown in Fig. 2A-D , the cell population that was triple-positive for CD34, CD133 ( Fig. 2A) , and CD309 (Fig. 2C) , represents 0.032‰ ± 0.019‰ of all PBMCs in the peripheral blood of healthy individuals. However, for CRC patients, 0.109‰ ± 0.070‰ of PBMCs were positive for CD34, CD133 (Fig. 2B), and CD309 (Fig. 2D) , which was significantly higher than that for the healthy donors (P < 0.01) (Fig. 2E) . Therefore, our data are consistent with previous findings that the number of cEPCs in CRC patients is significantly increased compared with that of healthy individuals [13] .
cEPC number as a tumor progression marker in CRC In order to understand the correlation among cEPC level, disease progression, and other clinicopathologic features of CRC patients, we compared the proportion of cEPC within PBMCs in the peripheral blood of 40 CRC patients. Our results showed a significant increase in the percentage of CD34 + CD133 + CD309 + cEPC cells in CRC patients with TNM Stages III and IV tumors (0.126‰ ± 0.077‰), as compared with those with early TNM Stage II tumors (0.072‰ ± 0.025‰, P = 0.018) (Fig. 3A) . However, no significant association between the cEPC levels and the gender of the CRC patients was found (male: 0.108‰ ± 0.074‰; female: 0.109‰ ± 0.062‰, P = 0.961) (Fig. 3B) . Taken together, these data suggest that cEPC levels in the peripheral blood can be used not only for the diagnosis of CRC, but also as a marker for tumor progression, as late stage CRC patients have increased cEPCs.
Increased cEPCs in CRC patients with higher serum CEA levels
As higher tumor micro-vascularization was found in CRC patients with higher serum levels of soluble CEA [13] , and bone marrowderived cEPCs were found to secrete pro-angiogenic factors in the tumor microenvironment [18] , it is possible that CEA may mediate cEPC-promoted tumor neovascularization. To address this question, 40 CRC patients were divided into two groups: one group with high CEA levels (≥5 ng/ml; 17 patients) and the other group with physiological levels of CEA (<5 ng/ml; 23 patients). cEPC levels in these two groups were compared, and results showed that the average PBMCs was significantly higher in patients with high CEA (0.148‰ ± 0.091‰) than in patients with low CEA (0.080‰ ± 0.024‰, P < 0.01) (Fig. 3C) . These data suggest that higher levels of serum CEA can indeed mediate cEPC-promoted tumor neovascularization.
Discussion
Despite significant advance in understanding CRC pathogenesis and molecular alterations, there is still need to develop biomarkers for early diagnosis, prevention, and treatment response prediction. Several non-invasive screening tests for early detection have been developed and implemented in the clinic based on DNA, RNA, and protein molecules in the stool, blood, or other biological fluids of CRC patients. However, challenges still remain to find new biomarkers with adequate specificity and sensitivity [3] . To this end, development of a series of biomarkers as a panel instead of using a single biomarker may be beneficial for early diagnosis and pre-selection of patient-specific therapies [3, 28] . CEA is one of the most widely used tumor markers worldwide, especially in gastrointestinal cancers such as CRCs [12] . Basal CEA level might constitute a predictor for cancer recurrence, metastasis, and response to therapies such as anti-VEGF agents [29] , although the sensitivity and specificity may not be optimal when used alone as a diagnostic marker for CRCs [30] . Recently, a link between serum CEA level and the degree of tumor vascularization was established [13] , which provided evidence that soluble CEA is sufficient to induce activation of ECs in the tumor microenvironment to facilitate neovascularization, a process that depends on integrin-3 signaling, but is independent of VEGF signaling [13] . These findings suggest that CEA levels may reflect differential tumor vascularization within the microenvironment, and that CEA may be involved in the therapeutic resistance to anti-VEGF signaling [29, 31] . In the present study, we showed that the serum CEA level of CRC patients is associated with the stage of the tumor, but not with the gender or age of the patients. Further examination of tumor biopsies is required to determine whether CEA levels correlate with the degree of tumor micro-vascularization. Our results, however, are consistent with previous findings that CEA can be used as a potential marker for tumor progression and disease prognosis [12] . Many cancers, including CRC, are associated with an increase in the number of cEPCs in the peripheral blood of the patients, which results in formation of tumor vasculatures and disease progression [18, 19, [21] [22] [23] 25, 26] . In our study, we also found a significant increase in the percentage of cEPC cells in CRC patients compared with those in healthy individuals. A positive association was found between the number of cEPC and TNM stages. Meanwhile, some researchers have shown negative results because of increased trafficking of cEPC in patients with colorectal cancer [32] and gastric cancer [33] . In addition, in these two studies the number of CRC patients involved was rather small (overall number is 17), and most of them was in TNM II stage in which the percentage of cEPC cells may not be significantly increased. Bone marrow-derived EPCs possess the properties of progenitor cells [15] and are capable of differentiating into mature ECs, as well as secreting pro-angiogenic factors that promote neovascularization [14] . Mobilization of EPCs from the bone marrow can occur in response to low oxygenation in tissues, such as during tissue ischemia or tumor hypoxia, and results in injury repair [34] or tumor vasculogenesis [18] . It has been suggested that this phenomenon seems to correlate with the systemic activation of the complement cascade (CC) molecules, such as hepatocyte growth factor and sphingosine-1-phosphate (S1P) [36] . Flow cytometric immunophenotyping experiments indicated that EPCs from the bone marrow were positive for cell surface markers CD34, CD133, and CD309 [14, 18, 24] . Using antibodies against these putative cEPC markers, we detected the cEPC population in PBMCs isolated from the peripheral blood of CRC patients. It was found that cEPC level was higher in CRC patients than in healthy individuals, and that cEPC level correlated with tumor stage, but not with the gender of the patients. These results are consistent with previous findings in various other cancer types: higher levels of cEPC and plasma pro-angiogenic factors were found in peripheral blood of hepatocellular carcinoma (HCC) [22] , non-small cell lung cancer (NSCLC) [26] , malignant glioma [25] , ovarian cancer [21] , and multiple myeloma [19] patients, when compared with those in healthy individuals. Thus, cEPC level can potentially be used not only as a prognostic marker but also as a predictor for response to therapeutic interventions such as those targeting tumor neoangiogenesis [20] . Interestingly, in the present study, we also found that cEPC level was higher in patients with a high CEA level, implying a role for CEA in cEPC-promoted tumor neovascularization. This neovascularization process depends on successful recruitment of EPCs from the bone marrow to the peripheral blood, then to the tumor, and the colonization of EPCs within the tumor microenvironment where they facilitate angiogenesis by secreting pro-angiogenic factors in a paracrine manner, or differentiate into mature ECs [18] . The successful integration of cEPCs into tumor vasculatures requires interaction of these cells with the resident ECs via selectins, integrins, and other adhesion molecules [18] , resulting in adhesion and migration of cEPCs into the tumor bed. Given that CEA can mediate EC behaviors, including adhesion, migration, and proliferation and that these processes depend on integrin signaling [37, 38] , it is likely that CEA also supports cEPC homing and activation in the tumor microenvironment. However, this hypothesis still remains to be confirmed.
In summary, our data support the notion that both cEPC and CEA levels can potentially be used as surrogate markers for tumor staging and disease prognosis [35] . In addition, the finding that the percentage of cEPCs within the PBMC population in the peripheral blood was higher in CRC patients with high serum CEA levels suggests a role for CEA in cEPC-mediated tumor neovascularization. Further research is required to determine whether CEA induces cEPC homing into the tumor microenvironment by promoting their adhesion, migration, or colonization via the activation of integrin signaling.
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+ CD133 + cEPCs in CRC patients divided by serum CEA level. The mean cEPC percentage for CRC patients with high CEA levels (≥5 ng/ml) was 0.148‰, while that for patients with physiological levels of CEA (<5 ng/ml) was 0.080‰. The amount of cEPCs in CRC patients with high serum CEAs was significantly higher than that in CRC patients with lower serum CEAs; **P < 0.01.
